Meristem Family Wealth’s Vertex Pharmaceuticals VRTX Stock Holding History

Meristem Family Wealth’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$329K	Sell	1,261 -8	-0.6%	-$1.9K	0.04%	249
2021 Q4	$279K	Hold	1,269	–	–	0.02%	311
2021 Q3	$230K	Buy	1,269 +259	+26%	+$50.6K	0.02%	364
2021 Q2	$204K	Hold	1,010	–	–	0.03%	309
2021 Q1	$217K	Hold	1,010	–	–	0.04%	223
2020 Q4	$239K	Hold	1,010	–	–	0.05%	196
2020 Q3	$275K	Hold	1,010	–	–	0.07%	153
2020 Q2	$293K	Hold	1,010	–	–	0.08%	142
2020 Q1	$240K	Sell	1,010 -15	-1%	-$3.44K	0.07%	152
2019 Q4	$224K	Buy	+1,025	New	+$207K	0.06%	177

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Meristem Family Wealth's VRTX Position: Q1 2022 in Review

Meristem Family Wealth reduced its Vertex Pharmaceuticals (VRTX) stake by 0.63% in Q1 2022, selling an estimated $1.9K and leaving 1,261 shares worth $329K. The position accounts for 0.04% of the portfolio, ranked #249.

Meristem Family Wealth first reported a position in VRTX in Q4 2019 and has held it in 10 quarters since. 1,071 funds tracked by Wall St. Rank hold VRTX as of Q1 2022.

Meristem Family Wealth held 1,261 shares of Vertex Pharmaceuticals worth $329K as of Q1 2022.
Meristem Family Wealth sold 8 Vertex Pharmaceuticals shares in Q1 2022, an estimated $1.9K.
Vertex Pharmaceuticals made up 0.04% of Meristem Family Wealth's portfolio in Q1 2022, its #249 holding.
Meristem Family Wealth first reported a position in Vertex Pharmaceuticals in Q4 2019 and has held it in 10 quarters since.
1,071 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2022.

Based on Meristem Family Wealth's 13F filing for Q1 2022, filed 11 May 2022.